Renatus Tactical Acquisition Corp I 8-K

What Happened

• Renatus Tactical Acquisition Corp I announced that director Matan Fattal resigned effective June 5, 2026, and also left the Audit, Compensation, and Nominating & Corporate Governance Committees. His resignation was not due to any dispute with the company or the Board.
• On June 8, 2026 the company notified Nasdaq that Fattal’s departure caused the company to fall out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) (audit committee must have at least three independent members) and 5605(b) (board must have a majority of independent directors).

Key Details

• Resignation date: June 5, 2026; Nasdaq notified: June 8, 2026.
• Committees affected: Audit Committee, Compensation Committee, Nominating & Corporate Governance Committee.
• Board composition after resignation: 2 independent directors, 2 non-independent directors, and 1 vacant seat to be filled by an independent director.
• The company intends to rely on Nasdaq’s cure periods under Rules 5605(c)(4)(B) and 5605(b)(1)(A) while it searches for a new independent director to join the Board and Audit Committee.

Why It Matters

• Governance and listing risk: the company is temporarily noncompliant with Nasdaq rules that require a majority-independent board and a three-member independent audit committee. If not remediated within Nasdaq’s cure periods, the company could face further regulatory action or risk to its Nasdaq listing.
• Investor oversight: having fewer independent directors and an understaffed audit committee can affect independent oversight of financial reporting and executive decisions—important considerations for shareholders even though no financial impact was reported in the filing.
• Next steps for investors: monitor announcements for the appointment of a new independent director and any Nasdaq communications about cure status or further action.